1934-49-2

Basic information

• Product Name: 4-(1-phenylcyclohexyl)morpholine hydrochloride (1:1)
• CAS NO: 1934-49-2
• Molecular Formula: C₁₆H₂₃NO*ClH
• Molecular Weight: 281.8209
• Mol File: 1934-49-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 347.3°C at 760 mmHg
• Flash Point: 102.6°C
• Vapor Pressure: 5.43E-05mmHg at 25°C
• CAS DataBase Reference: 4-(1-phenylcyclohexyl)morpholine hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-phenylcyclohexyl)morpholine hydrochloride (1:1)(1934-49-2)
• EPA Substance Registry System: 4-(1-phenylcyclohexyl)morpholine hydrochloride (1:1)(1934-49-2)

Safety Data

• Hazardous Substances Data: 1934-49-2(Hazardous Substances Data)

Upstream product

• 108-86-1 bromobenzene 
• 42419-59-0 1-(morpholin-4-yl)cyclohexanecarbonitrile 
• 108-94-1 cyclohexanone 

Relevant articles and documents

New morpholine analogues of phencyclidine: Chemical synthesis and pain perception in rats

Phencyclidine (PCP, I) and most its derivatives have demonstrated some pharmacological effects. Accordingly, in this study, the new methoxy (III) and hydroxy-methyl (IV) morpholine PCP derivatives were synthesized. The acute and chronic pain activities of these drugs (III, IV) were investigated by tail immersion and formalin tests on rats and the results were compared with those in PCP, PCM (PCP-morpholine, II), and methyl-PCM (V). Findings indicated that III (6 mg/kg, i.p.) generates more analgesic effects in tail immersion test in comparison with I and II in 20, 40, 45 and 55 min post-injection. These effects were observed in 10, 20, 40, 45 and 50 min after the application of IV (at the same dosage). This analgesic effect was markedly seen in 20, 40, 45 and 50 min after compound IVs application in comparison with the drugs (I-V). In formalin test analysis, the acute chemical pain (Phase I) could not be affected by any drugs (I-V) while chronic formalin pain would be diminished by these new synthesized drugs (III and IV), especially in late Phase II, compared to I and II at the dosage of 6 mg/kg. It is, therefore, concluded that these new synthesized PCP derivates including methoxy-PCM (III) and hydroxy-methyl-PCM (IV) could substantially and respectively diminish acute thermal and chronic chemical pains.